CD28 and acute myeloid leukemia: A recent study reported the first results of a Phase I clinical trial investigating the safety and efficacy of autologous third generation CD123 CAR-T cells generated with a vector containing a CD123-CAR with a CD28 signaling domain and a CD20 safety switch in a population of pediatric AML patients with relapsed/refractory disease [118] (Table 1).